HIV Infections Clinical Trial
Official title:
Adopting and Demonstrating the Adaptation of Prevention Techniques (ADAPT), Harlem United Community AIDS Center
This project will pilot test a step-by-step guide for community-based organizations to engage in evidence-based adaptation of interventions previously shown to be effective in research settings for use in real world applications. The main purpose of this program is to improve understanding of the processes needed for adapting evidence-based behavioral interventions to fit new conditions or populations and to pilot CDC-developed draft guidance for adaptation. The second purpose of the program is to increase the number of effective behavioral HIV prevention interventions for 18-24 year old sero-positive men of color who have sex with other men (MSM of color).
The Adopting and Demonstrating the Adaptation of Prevention Techniques project (referred to
as ADAPTATION throughout this protocol) responds to concerns from the field that existing
interventions do not address the HIV prevention needs of diverse and often unstudied
populations. This project will pilot test a step-by-step guide for community-based
organizations to engage in evidence-based adaptation of interventions previously shown to be
effective in research settings for use in real world applications. The main purpose of this
program is to improve understanding of the processes needed for adapting evidence-based
behavioral interventions to fit new conditions or populations and to pilot CDC-developed
draft guidance for adaptation. The second purpose of the program is to increase the number
of effective behavioral HIV prevention interventions for 18-24 year old sero-positive men of
color who have sex with other men (MSM of color).
Harlem United Community AIDS Center is one of five sites originally funded through Program
Announcement 04064 and selected to receive a supplement to conduct adaptation activities.
Under Program Announcement 04064, Harlem United, a community-based organization with over 16
years of experience providing quality HIV services to the Harlem and South Bronx
communities, was funded to implement a multi-faceted, HIV prevention program. The program
combines rapid testing, access to care, and an evidenced-based, group-level behavioral
intervention (i.e., Healthy Relationships) for sero-positive, heterosexual men and women of
color. Healthy Relationships is a five-session, small group-level intervention for persons
living with HIV/AIDS that promotes the development of decision-making and problem-solving
skills that enable participants to make informed and safe decisions about disclosure and
behaviors. Preliminary evaluation efforts suggest that this service model is effective in
reducing risk behaviors among the general population, but its appropriateness and
effectiveness for specific sub-populations has yet to be fully demonstrated. The original
research for Healthy Relationships was conducted in Atlanta, Georgia. Approximately half of
the participants identified as gay and the study population had a mean age of 40 years.
Harlem United will adapt the Healthy Relationships intervention for young sero-positive MSM
of color between the ages of 18-24 who reside in Harlem, New York. Further adaptation also
may include adding decision-making for disclosure with needle sharing partners.
The goal of Harlem United's ADAPTATION project is to evaluate efforts to adapt and implement
the Healthy Relationships intervention for young sero-positive MSM of color by: 1)
documenting the resources and activities required to adapt and implement the Healthy
Relationships intervention model for young sero-positive MSM of color; 2) optimizing service
delivery; 3) measuring the effectiveness of the newly-adapted intervention; and 4) assessing
CDC's guidance for adapting effective behavioral interventions for new populations.
;
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |